Finding new targets for immunotherapy in triple-negative breast cancer
Identifying Chemo-Neoepitopes for Immunotherapy Interventions Against Triple-Negative Breast Cancer
This study is looking for ways to make treatments better for people with advanced triple-negative breast cancer by finding special markers on tumors that can help the immune system fight the cancer more effectively, especially after chemotherapy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10946981 on NIH RePORTER |
What this research studies
This research focuses on improving treatment options for patients with advanced triple-negative breast cancer (TNBC) by identifying specific tumor antigens that can enhance the effectiveness of immunotherapy. The approach involves analyzing how chemotherapy affects cancer cells and generates new antigens that can be recognized by the immune system. By understanding these mechanisms, the research aims to develop better immunotherapy strategies that could lead to improved patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced triple-negative breast cancer who are undergoing or have undergone chemotherapy.
Not a fit: Patients with non-triple-negative breast cancer or those who are not receiving chemotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with triple-negative breast cancer, potentially extending survival rates.
How similar studies have performed: Previous research has shown promising results in enhancing immunotherapy effectiveness through the identification of tumor antigens, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
Buffalo, United States
- Roswell Park Cancer Institute Corp — Buffalo, United States (Active)
Researchers
- Principal investigator: Ionov, Yurij — Roswell Park Cancer Institute Corp
- Study coordinator: Ionov, Yurij
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.